Primaquine Diphosphate

• CAT Number: I004391
• CAS Number: 63-45-6
• Molecular Formula: C15H21N3O • 2H3PO4
• Molecular Weight: 455.3
• Purity: ≥95%
• Target: Antimalaria
• Solubility: H2O: ≥ 35 mg/mL
• Storage: 2-8°C
• IUPAC Name: 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;phosphoric acid
• InChI: InChI=1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4)
• InChIKey: GJOHLWZHWQUKAU-UHFFFAOYSA-N
• SMILES: CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2.OP(=O)(O)O.OP(=O)(O)O

Primaquine（Cat No.:I004391） is a vital anti-malarial drug that holds unique properties in the treatment of malaria. It is the only widely accessible medication that effectively prevents relapse in cases of vivax and ovale malaria, two types of malaria caused by Plasmodium parasites. Additionally, primaquine serves as the sole potent gametocytocidal for falciparum malaria, targeting the sexual stage of the parasite’s life cycle.

Reference

1:Optimization of primaquine diphosphate tablet formulation for controlled drug release using the mixture experimental design. Duque MD, Kreidel RN, Taqueda ME, Baby AR, Kaneko TM, Velasco MV, Consiglieri VO.Pharm Dev Technol. 2013 Sep-Oct;18(5):1247-54. doi: 10.3109/10837450.2012.693508. Epub 2012 Jun 7. PMID: 22670808 2:Analysis of quinocide in unprocessed primaquine diphosphate and primaquine diphosphate tablets using gas chromatography-mass spectrometry with supersonic molecular beams. Brondz I, Fialkov AB, Amirav A.J Chromatogr A. 2009 Jan 30;1216(5):824-9. doi: 10.1016/j.chroma.2008.11.043. Epub 2008 Nov 21. Erratum in: J Chromatogr A. 2009 Mar 20;1216(12):2609-10. PMID: 19108846 3:Nature of the main contaminant in the drug primaquine diphosphate: SFC and SFC-MS methods of analysis. Brondz I, Ekeberg D, Bell DS, Annino AR, Hustad JA, Svendsen R, Vlachos V, Oakley P, Langley GJ, Mohini T, Amaury CG, Mikhalitsyn F.J Pharm Biomed Anal. 2007 Feb 19;43(3):937-44. Epub 2006 Oct 31. PMID: 17079107 4:Primaquine diphosphate: comprehensive profile. Al-Badr AA.Profiles Drug Subst Excip Relat Methodol. 2005;32:153-208. doi: 10.1016/S0099-5428(05)32007-7. Epub 2006 Jan 17. No abstract available. PMID: 22469087 5:In vitro and in vivo evaluation of albumin-encapsulated primaquine diphosphate prepared by nebulization into heated oil. Green MD, D/’Souza MJ, Holbrook JM, Wirtz RA.J Microencapsul. 2004 Jun;21(4):433-44. PMID: 15513749 6:Nature of the main contaminant in the anti malaria drug primaquine diphosphate: a qualitative isomer analysis. Brondz I, Mantzilas D, Klein U, Ekeberg D, Hvattum E, Lebedeva MN, Mikhailitsyn FS, Souleimanov GD, Røe J.J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Feb 5;800(1-2):211-23. PMID: 14698257 7:Dissociation and electrooxidation of primaquine diphosphate as an approach to the study of anti-chagas prodrugs mechanism of action. La-Scalea MA, Chin CM, Cruz ML, Serrano SH, Ferreira EI.Bioelectrochemistry. 2001 Jan;53(1):55-9. PMID: 11206925 8:Characterization, in vitro and in vivo studies on primaquine diphosphate liposomes. Arica B, Ozer AY, Ercan MT, Hincal AA.J Microencapsul. 1995 Sep-Oct;12(5):469-85. PMID: 8544091 9:Structure of the anti-malarial drug primaquine diphosphate. Rubin JR, Swaminathan P, Sundaralingam M.Acta Crystallogr C. 1992 Feb 15;48 ( Pt 2):379-82. PMID: 1627276 10:Primaquine diphosphate: inhibition of Newcastle disease virus replication. Burdick JR, Durand DP.Antimicrob Agents Chemother. 1974 Oct;6(4):460-4. PMID: 4157345 Free PMC Article